These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 25936303)
1. First data from the German Lipoprotein Apheresis Registry (GLAR). Schettler VJ; Neumann CL; Peter C; Zimmermann T; Julius U; Roeseler E; Heigl F; Ramlow W; Blume H; Atheroscler Suppl; 2015 May; 18():41-4. PubMed ID: 25936303 [TBL] [Abstract][Full Text] [Related]
2. Current insights into the German Lipoprotein Apheresis Registry (GLAR) - Almost 5 years on. Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Roeseler E; Heigl F; Grützmacher P; Blume H; Atheroscler Suppl; 2017 Nov; 30():50-55. PubMed ID: 29096861 [TBL] [Abstract][Full Text] [Related]
3. The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on. Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Roeseler E; Heigl F; Grützmacher P; Blume H; Vogt A; Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):44-49. PubMed ID: 28233268 [TBL] [Abstract][Full Text] [Related]
4. The German Lipid Apheresis Registry - remaining to be established. Schettler V; Jaeger BR; Klingel R; Atheroscler Suppl; 2009 Dec; 10(5):59-61. PubMed ID: 20129377 [TBL] [Abstract][Full Text] [Related]
5. Current view: indications for extracorporeal lipid apheresis treatment. Schettler V; Neumann CL; Hulpke-Wette M; Hagenah GC; Schulz EG; Wieland E; Clin Res Cardiol Suppl; 2012 Jun; 7(Suppl 1):15-9. PubMed ID: 22528134 [TBL] [Abstract][Full Text] [Related]
6. Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levels. Schettler VJ; Neumann CL; Peter C; Zimmermann T; Julius U; Roeseler E; Heigl F; Clin Res Cardiol Suppl; 2015 Apr; 10(Suppl 1):14-20. PubMed ID: 25652812 [TBL] [Abstract][Full Text] [Related]
7. Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease--Additional particular aspects of the Pro(a)LiFe multicenter trial. Klingel R; Heibges A; Fassbender C Atheroscler Suppl; 2015 May; 18():35-40. PubMed ID: 25936302 [TBL] [Abstract][Full Text] [Related]
8. Actual situation of lipoprotein apheresis in Saxony in 2013. Emmrich U; Hohenstein B; Julius U Atheroscler Suppl; 2015 May; 18():215-25. PubMed ID: 25936329 [TBL] [Abstract][Full Text] [Related]
9. Rationale and design of MultiSELECt: A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by lipoprotein apheresis on Cardiovascular outcomes. Hohenstein B; Julius U; Lansberg P; Jaeger B; Mellwig KP; Weiss N; Graehlert X; Roeder I; Ramlow W Atheroscler Suppl; 2017 Nov; 30():180-186. PubMed ID: 29096835 [TBL] [Abstract][Full Text] [Related]
10. Lipoprotein apheresis in Germany - Still more commonly indicated than implemented. How can patients in need access therapy? Heigl F; Pflederer T; Klingel R; Hettich R; Lotz N; Reeg H; Schettler VJJ; Roeseler E; Grützmacher P; Hohenstein B; Julius U Atheroscler Suppl; 2019 Dec; 40():23-29. PubMed ID: 31818446 [TBL] [Abstract][Full Text] [Related]
12. Effects of Lipoprotein apheresis on the Lipoprotein(a) levels in the long run. Groß E; Hohenstein B; Julius U Atheroscler Suppl; 2015 May; 18():226-32. PubMed ID: 25936330 [TBL] [Abstract][Full Text] [Related]
13. Factors inducing cardiovascular events in patients treated by lipoprotein apheresis. Taseva K; Fischer S; Passauer J; Weiss N; Bornstein SR; Julius U Atheroscler Suppl; 2013 Jan; 14(1):45-50. PubMed ID: 23357140 [TBL] [Abstract][Full Text] [Related]
14. Adverse events of lipoprotein apheresis and immunoadsorption at the Apheresis Center at the University Hospital Dresden. Dittrich-Riediger J; Schatz U; Hohenstein B; Julius U Atheroscler Suppl; 2015 May; 18():45-52. PubMed ID: 25936304 [TBL] [Abstract][Full Text] [Related]
15. Current situation of lipoprotein apheresis in Saxony. Julius U; Taseva K; Fischer S; Passauer J; Bornstein SR Atheroscler Suppl; 2013 Jan; 14(1):51-5. PubMed ID: 23357141 [TBL] [Abstract][Full Text] [Related]
16. The incidence of cardiovascular events is largely reduced in patients with maximally tolerated drug therapy and lipoprotein apheresis. A single-center experience. Sampietro T; Sbrana F; Bigazzi F; Ripoli A; Dal Pino B; Pasanisi EM; Petersen C; Coceani M; Luciani R; Pianelli M Atheroscler Suppl; 2015 May; 18():268-72. PubMed ID: 25936336 [TBL] [Abstract][Full Text] [Related]
17. Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines. Klingel R; Heibges A; Fassbender C; Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):38-43. PubMed ID: 28185214 [TBL] [Abstract][Full Text] [Related]
18. Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern. von Dryander M; Fischer S; Passauer J; Müller G; Bornstein SR; Julius U Atheroscler Suppl; 2013 Jan; 14(1):39-44. PubMed ID: 23357139 [TBL] [Abstract][Full Text] [Related]
19. Detailed description of the cardiovascular situation in patients who have started lipoprotein apheresis treatment. Schampera S; Fischer S; Weiss N; Julius U Atheroscler Suppl; 2015 May; 18():209-14. PubMed ID: 25936328 [TBL] [Abstract][Full Text] [Related]
20. Lipoprotein apheresis standard for apheresis competence centers--an updated synthesis and amendment to pre-existing standards. Heigl F; Hettich R; Eder B; Arendt R Atheroscler Suppl; 2013 Jan; 14(1):57-65. PubMed ID: 23357142 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]